Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas

Carcinogenesis

Volumn 27, Issue 12, 2006, Pages 2497-2510

  Ueda, Shinobu ^a,b   Fukamachi, Katsumi ^a   Matsuoka, Yoichiro ^b,d   Takasuka, Nobuo ^b   Takeshita, Fumitaka ^b   Naito, Akihiro ^b   Iigo, Masaaki ^b   Alexander, David B ^a   Moore, Malcolm A ^a   Saito, Izumu ^c   Ochiya, Takahiro ^b   Tsuda, Hiroyuki ^a,b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; BETA CATENIN; CHYMOTRYPSIN; CRE RECOMBINASE; CYCLOOXYGENASE 2; CYTOKERATIN 19; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HA RAS G12V PROTEIN; MATRILYSIN; ONCOPROTEIN;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; RAT; TISSUE SPECIFICITY; TRANSGENE; TRANSGENIC ANIMAL; VIRUS INFECTION;

ADENOCARCINOMA; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENES, RAS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; RATS;

EID: 33845361229     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl090     Document Type: Article

References (60)

1. Beger,H.G., Rau,B., Gansauge,F., Poch,B. and Link,K.H. (2003) Treatment of pancreatic cancer: Challenge of the facts. World J. Surg., 27, 1075-1084.
2. Greenlee,R.T., Hill-Harmon,M.B., Murray,T. and Thun,M. (2001) Cancer statistics., 2001. CA. Cancer J. Clin., 51, 15-36.
3. Jemal,A., Murray,T., Samuels,A., Ghafoor,A., Ward,E. and Thun,M.J. (2003) Cancer statistics., 2003. CA. Cancer J. Clin., 53, 5-26.
4. Macdonald,J.S. (2004) Clinical overview: Adjuvant therapy of gastrointestinal cancer. Cancer Chemother. Pharmacol., 54 (Suppl. 1), S4-S11.
5. Moore,M.A., Bannasch,P., Satoh,T., Hacker,H.J. and Ito,N. (1987) Immunohistochemically demonstrated increase in glutathione S-transferase species in propylnitrosamine-induced focal proliferative and neoplastic Syrian hamster pancreatic lesions. Virchows. Arch. B Cell. Pathol. Incl. Mol. Pathol., 52, 479-488.
6. Majima,T., Tsujiuchi,T., Tsutsumi,M., Tsunoda,T. and Konishi,Y. (1997) Mutations of K-ras but not p53 genes in biliary duct and pancreatic duct carcinomas induced in hamsters by cholecystoduodenostomy with dissection of the common duct followed by N-nitrosobis(2-oxopropyl)amine. Cancer Lett., 118, 47-53.
7. Almoguera,C., Shibata,D., Forrester,K., Martin,J., Arnheim,N. and Perucho,M. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53, 549-554.
8. Hilgers,W. and Kern,S.E. (1999) Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer, 26, 1-12.
9. Smit,V.T., Boot,A.J., Smits,A.M., Fleuren,G.J., Cornelisse,C.J. and Bos,J.L. (1988) KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res., 16, 7773-7782.
10. Konishi,Y., Mizumoto,K., Kitazawa,S., Tsujiuchi,T., Tsutsumi,M. and Kamano,T. (1990) Early ductal lesions of pancreatic carcinogenesis in animals and humans. Int. J. Pancreatol., 7, 83-89.
11. Mizumoto,K., Tsutsumi,M., Denda,A. and Konishi,Y. (1988) Rapid production of pancreatic carcinoma by initiation with N-nitroso-bis(2-oxopropyl)amine and repeated augmentation pressure in hamsters. J. Natl Cancer Inst., 80, 1564-1567.
12. Standop,J., Schneider,M.B., Ulrich,A. and Pour,P.M. (2001) Experimental animal models in pancreatic carcinogenesis: Lessons for human pancreatic cancer. Dig. Dis., 19, 24-31.
13. Grippo,P.J., Nowlin,P.S., Demeure,M.J., Longnecker,D.S. and Sandgren,E.P. (2003) Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res., 63, 2016-2019.
14. Quaife,C.J., Pinkert,C.A., Ornitz,D.M., Palmiter,R.D. and Brinster,R.L. (1987) Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell, 48, 1023-1034.
15. Brembeck,F.H., Schreiber,F.S., Deramaudt,T.B., Craig,L., Rhoades,B., Swain,G., Grippo,P., Stoffers,D.A., Silberg,D.G. and Rustgi,A.K. (2003) The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res., 63, 2005-2009.
16. Hingorani,S.R., Petricoin,E.F., Maitra,A. et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4, 437-450.
17. Aguirre,A.J., Bardeesy,N., Sinha,M., Lopez,L., Tuveson,D.A., Horner,J., Redston,M.S. and DePinho,R.A. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes. Dev., 17, 3112-3126.
18. Tsuda,H., Fukamachi,K., Ohshima,Y., Ueda,S., Matsuoka,Y., Hamaguchi,T., Ohnishi,T., Takasuka,N. and Naito,A. (2005) High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: A cancer-prone animal model. Cancer Sci., 96, 309-316.
19. Naito,A., Suzuki,A., Ueda,S., Nomoto,H., Toriyama-Baba,H., Asamoto,M. and Tsuda,H. (2004) Preferential mammary carcinogenic effects of 2-amino-1-methyl-6-phenylimidazo (4,5-b)pyridine (PhIP) in human c-Ha-ras proto-oncogene transgenic rats. Cancer Sci., 95, 399-403.
20. Park,C.B., Fukamachi,K., Takasuka,N., Han,B.S., Kim,C.K., Hamaguchi,T., Fujita,K., Ueda,S. and Tsuda,H. (2004) Rapid induction of skin and mammary tumors in human c-Ha-ras proto-oncogene transgenic rats by treatment with 7,12-dimethylbenz(a)anthracene followed by 12-O-tetradecanoylphorbol 13-acetate. Cancer Sci., 95, 205-210.
21. Tsuda,H., Asamoto,M., Ochiya,T., Toriyama-Baba,H., Naito,A., Ota,T., Sekiya,T. and Terada,M. (2001) High susceptibility of transgenic rats carrying the human c-Ha-ras proto-oncogene to chemically-induced mammary carcinogenesis. Mutat. Res., 477, 173-182.
22. Kanegae,Y., Lee,G., Sato,Y., Tanaka,M., Nakai,M., Sakaki,T., Sugano,S. and Saito,I. (1995) Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res., 23, 3816-3821.
23. Capon,D.J., Chen,E.Y., Levinson,A.D., Seeburg,P.H. and Goeddel,D.V. (1983) Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature, 302, 33-37.
24. Reddy,E.P. (1983) Nucleotide sequence analysis of the T24 human bladder carcinoma oncogene. Science, 220, 1061-1063.
25. Asamoto,M., Ochiya,T., Toriyama-Baba,H., Ota,T., Sekiya,T., Terada,M. and Tsuda,H. (2000) Transgenic rats carrying human c-Ha-ras protooncogenes are highly susceptible to N-methyl-N-nitrosourea mammary carcinogenesis. Carcinogenesis, 21, 243-249.
26. Kanegae,Y., Makimura,M. and Saito,I. (1994) A simple and efficient method for purification of infectious recombinant adenovirus. Jpn. J. Med. Sci. Biol., 47, 157-166.
27. Taniguchi,H., Yamato,E., Tashiro,F., Ikegami,H., Ogihara,T. and Miyazaki,J. (2003) Beta-cell neogenesis induced by adenovirusmediated gene delivery of transcription factor pdx-1 into mouse pancreas. Gene Ther., 10, 15-23.
28. Sambrook,J. and Russell,D.W. (2001) Molecular Cloning A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
29. Bardeesy,N. and DePinho,R.A. (2002) Pancreatic cancer biology and genetics. Nat. Rev. Cancer, 2, 897-909.
30. Hruban,R.H., Adsay,N.V., Albores-Saavedra,J et al. (2001) Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol., 25, 579-586.
31. Crawford,H.C., Scoggins,C.R., Washington,M.K., Matrisian,L.M. and Leach,S.D. (2002) Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J. Clin. Invest., 109, 1437-1444.
32. Jones,L.E., Humphreys,M.J., Campbell,F., Neoptolemos,J.P. and Boyd,M.T. (2004) Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival. Clin. Cancer Res., 10, 2832-2845.
33. Ohnami,S., Matsumoto,N., Nakano,M., Aoki,K., Nagasaki,K., Sugimura,T., Terada,M. and Yoshida,T. (1999) Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer Res., 59, 5565-5571.
34. Schmid,R.M (2002) Acinar-to-ductal metaplasia in pancreatic cancer development. J. Clin. Invest., 109, 1403-1404.
35. Jimenez,R.E., Z'Graggen,K., Hartwig,W., Graeme-Cook,F., Warshaw,A.L. and Fernandez-del Castillo,C. (1999) Immunohistochemical characterization of pancreatic tumors induced by dimethylbenzanthracene in rats. Am. J. Pathol., 154, 1223-1229.
36. Bockman,D.E., Guo,J., Buchler,P., Muller,M.W., Bergmann,F. and Friess,H. (2003) Origin and development of the precursor lesions in experimental pancreatic cancer in rats. Lab. Invest., 83, 853-859.
37. Flaks,B., Moore,M.A. and Flaks,A. (1982) Ultrastructural analysis of pancreatic carcinogenesis. V. Changes in differentiation of acinar cells during chronic treatment with N-nitrosobis(2-hydroxypropyl)amine. Carcinogenesis., 3, 485-498.
38. Pettengill,O.S., Faris,R.A., Bell,R.H.,Jr, Kuhlmann,E.T. and Longnecker,D.S. (1993) Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas. Am. J. Pathol., 143, 292-303.
39. Arias,A.E. and Bendayan,M. (1993) Differentiation of pancreatic acinar cells into duct-like cells in vitro. Lab. Invest., 69, 518-530.
40. De Lisle,R.C. and Logsdon,C.D. (1990) Pancreatic acinar cells in culture: Expression of acinar and ductal antigens in a growth-related manner. Eur. J. Cell Biol., 51, 64-75.
41. Hall,P.A. and Lemoine,N.R. (1992) Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. J. Pathol., 166, 97-103.
42. Stanger,B.Z., Stiles,B., Lauwers,G.Y. et al. (2005) Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell, 8, 185-195.
43. Cowgill,S.M. and Muscarella,P. (2003) The genetics of pancreatic cancer. Am. J. Surg., 186, 279-286.
44. Hruban,R.H., Wilentz,R.E. and Kern,S.E. (2000) Genetic progression in the pancreatic ducts. Am. J. Pathol., 156, 1821-1825.
45. Schneider,G. and Schmid,R.M. (2003) Genetic alterations in pancreatic carcinoma. Mol. Cancer, 2, 15.
46. Sirivatanauksorn,V., Sirivatanauksorn,Y. and Lemoine,N.R. (1998) Molecular pattern of ductal pancreatic cancer. Langenbecks. Arch. Surg., 383, 105-115.
47. Shi,Y. and Massague,J. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113, 685-700.
48. Gu,Y., Turck,C.W. and Morgan,D.O. (1993) Inhibition of CDK2 activity in vivo by an associated 20 K regulatory subunit. Nature., 366, 707-710.
49. Harada,K. and Ogden,G.R. (2000) An overview of the cell cycle arrest protein, p21(WAF1). Oral. Oncol., 36, 3-7.
50. Roninson,I.B (2003) Tumor cell senescence in cancer treatment. Cancer Res., 63, 2705-2715.
51. Weinberg,W.C. and Denning,M.F. (2002) P21Waf1 control of epithelial cell cycle and cell fate. Crit. Rev. Oral. Biol. Med., 13, 453-464.
52. Bocchetta,M. and Carbone,M. (2004) Epidemiology and molecular pathology at crossroads to establish causation: Molecular mechanisms of malignant transformation. Oncogene., 23, 6484-6491.
53. Hahn,W.C. and Weinberg,R.A. (2002) Rules for making human tumor cells. N. Engl. J. Med., 347, 1593-1603.
54. Hahn,W.C. and Weinberg,R.A. (2002) Modelling the molecular circuitry of cancer. Nat. Rev. Cancer, 2, 331-341.
55. Sherr,C.J. and McCormick,F. (2002) The RB and p53 pathways in cancer. Cancer Cell, 2, 103-112.
56. Iwakuma,T. and Lozano,G. (2003) MDM2, an introduction. Mol. Cancer Res., 1, 993-1000.
57. Zhang,Y. and Xiong,Y. (2001) Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell. Growth Differ., 12, 175-186.
58. Fu,M., Wang,C., Li,Z., Sakamaki,T. and Pestell,R.G. (2004) Mini review: Cyclin D1: Normal and abnormal functions. Endocrinology., 145, 5439-5447.
59. Ruas,M. and Peters,G. (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta., 1378, F115-F177.
60. Gerdes,B., Ramaswamy,A., Ziegler,A., Lang,S.A., Kersting,M., Baumann,R., Wild,A., Moll,R., Rothmund,M. and Bartsch,D.K. (2002) p16INK4a is a prognostic marker in resected ductal pancreatic cancer: An analysis of p16INK4a, p53, MDM2, an Rb. Ann. Surg., 235, 51-59.